Quintessence debuts first ‘living’ artificial cell for CGT bio-separation
Quintessence Biotech has launched a bio-separation tool to reduce the manufacturing bottleneck suffered by cell and gene therapies (CGTs), creating…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
Excalipoint debuts with $68.7m to progress TCE pipeline
Chinese biotech Excalipoint Therapeutics is looking to progress its pipeline of T-cell engager (TCE) therapies in immunology and oncology as…
-
Navigating the valley of death: a how-to from an investor’s perspective
In a crowded biotech landscape full of potential, especially in advanced therapeutic medicinal products (ATMPs), companies must differentiate themselves from…
-
GSK’s RSV jab secures FDA label expansion to larger adult population
GSK has secured a label expansion for its respiratory syncytial virus (RSV) vaccine, Arexvy, from the US Food and Drug…
-
Widespread US shift from prescription to OTC lies in pharma’s hands
In an interview from February 2026, commissioner of the US Food and Drug Administration (FDA), Marty Makary, said that “everything…
-
Parkinson’s research reaches “pivotal” stage, but barriers remain
Preclinical and clinical research focused on Parkinson’s disease has reached a “pivotal point”, but funding barriers and outdated clinical trial…
-
Vima banks $100m in Series A to progress Parkinson’s drug
Massachusetts-based biotech Vima Therapeutics has extended its Series A financing by $40m to advance its investigational Parkinson’s and dystonia pill,…
-
FDA issues warning to Novo Nordisk on unreported semaglutide safety events
Novo Nordisk has received a warning letter from the US Food and Drug Administration (FDA) related to the company’s failure…
-
UK health authorities join forces to champion foreign infectious disease trials
Health divisions within the UK government and British non-profit organisations have banded together to support infectious disease trials in Africa,…
-
FDA homes in on biosimilar accessibility in new draft guidance
The US Food and Drug Administration (FDA) has further updated its regulatory framework around biosimilar medicines in a bid to…